<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/archiving/3.0/archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-09541</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0006105</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology/Immunity to Infections</subject><subject>Immunology/Leukocyte Activation</subject><subject>Virology/Host Antiviral Responses</subject></subj-group></article-categories><title-group><article-title>Lactate Dehydrogenase-Elevating Virus Induces Systemic Lymphocyte Activation via TLR7-Dependent IFN&#x003b1; Responses by Plasmacytoid Dendritic Cells</article-title><alt-title alt-title-type="running-head">LDV Induced IFN&#x003b1; Responses</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ammann</surname><given-names>Christoph G.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Messer</surname><given-names>Ronald J.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Peterson</surname><given-names>Karin E.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Hasenkrug</surname><given-names>Kim J.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Kallas</surname><given-names>Esper Georges</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="aff1"><addr-line>Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America</addr-line></aff><aff id="edit1">University of Sao Paulo, Brazil</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>khasenkrug@nih.gov</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: CGA KJH. Performed the experiments: CGA RJM KEP. Analyzed the data: CGA. Wrote the paper: CGA KJH.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>1</day><month>7</month><year>2009</year></pub-date><volume>4</volume><issue>7</issue><elocation-id>e6105</elocation-id><history><date date-type="received"><day>1</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>25</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Lactate dehydrogenase-elevating virus (LDV) is a natural infectious agent of mice. Like several other viruses, LDV causes widespread and very rapid but transient activation of both B cells and T cells in lymphoid tissues and the blood. The mechanism of this activation has not been fully described and is the focus of the current studies.</p></sec><sec><title>Principal Findings</title><p>A known inducer of early lymphocyte activation is IFN&#x003b1;, a cytokine strongly induced by LDV infection. Neutralization of IFN&#x003b1; in the plasma from infected mice ablated its ability to activate lymphocytes <italic>in vitro</italic>. Since the primary source of virus-induced IFN&#x003b1; <italic>in vivo</italic> is often plasmacytoid dendritic cells (pDC's), we depleted these cells prior to LDV infection and tested for lymphocyte activation. Depletion of pDC's <italic>in vivo</italic> eradicated both the LDV-induced IFN&#x003b1; response and lymphocyte activation. A primary receptor in pDC's for single stranded RNA viruses such as LDV is the toll-like receptor 7 (TLR7) pattern recognition receptor. Infection of TLR7-knockout mice revealed that both the IFN&#x003b1; response and lymphocyte activation were dependent on TLR7 signaling <italic>in vivo</italic>. Interestingly, virus levels in both TLR7 knockout mice and pDC-depleted mice were indistinguishable from controls indicating that LDV is largely resistant to the systemic IFN&#x003b1; response.</p></sec><sec><title>Conclusion</title><p>Results indicate that LDV-induced activation of lymphocytes is due to recognition of LDV nucleic acid by TLR7 pattern recognition receptors in pDC's that respond with a lymphocyte-inducing IFN&#x003b1; response.</p></sec></abstract><counts><page-count count="5"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Lactate dehydrogenase-elevating virus (LDV) is a small, positive sense, single stranded RNA virus of the Arteriviridae family, related to coronaviruses such as the severe acute respiratory syndrome (SARS) virus <xref ref-type="bibr" rid="pone.0006105-Drosten1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Ksiazek1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Peiris1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Plagemann1">&#x0005b;4&#x0005d;</xref>. It is a natural infectious agent of mice that causes very rapid lytic infections generally restricted to a minor subset of non-essential macrophages involved in scavenging extracellular lactate dehydrogenase <xref ref-type="bibr" rid="pone.0006105-Plagemann2">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Ritzi1">&#x0005b;6&#x0005d;</xref>. The rapid loss of this subset results in the elevated lactate dehydrogenase levels for which the virus is named <xref ref-type="bibr" rid="pone.0006105-Riley1">&#x0005b;7&#x0005d;</xref>. Virus titers peak within the first day of infection as susceptible target cells are depleted, and then the infection is maintained at a much lower chronic level dependent on the replenishment of new macrophage targets <xref ref-type="bibr" rid="pone.0006105-Onyekaba1">&#x0005b;8&#x0005d;</xref>. LDV establishes chronic infections regardless of mouse strain, age, sex or immune-status <xref ref-type="bibr" rid="pone.0006105-Plagemann2">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Onyekaba1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Stueckemann1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-vandenBroek1">&#x0005b;10&#x0005d;</xref>. No clinical signs are typically associated with LDV infections, although co-infection with retroviruses can lead to CNS disease under certain circumstances <xref ref-type="bibr" rid="pone.0006105-Anderson1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Contag1">&#x0005b;12&#x0005d;</xref>, and mice infected with LDV have suppressed immune responses <xref ref-type="bibr" rid="pone.0006105-Marques1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Notkins1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Howard1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Robertson1">&#x0005b;16&#x0005d;</xref>. We recently found that acute infection with LDV induced a state of partial and transient activation in the vast majority of splenic lymphocytes. Activation was characterized by high surface expression of the very early activation marker CD69 <xref ref-type="bibr" rid="pone.0006105-Robertson1">&#x0005b;16&#x0005d;</xref>. CD69 is the first surface marker known to be upregulated during the activation of lymphocytes and has recently been shown to interact with S1P1 to inhibit the egress of lymphocytes from lymphoid tissues <xref ref-type="bibr" rid="pone.0006105-Shiow1">&#x0005b;17&#x0005d;</xref>. CD69 expression is upregulated by T cell receptor (TCR) ligation <xref ref-type="bibr" rid="pone.0006105-LopezCabrera1">&#x0005b;18&#x0005d;</xref> but is not dependent upon it and can be induced by inflammatory cytokines such as IFN&#x003b1; <xref ref-type="bibr" rid="pone.0006105-Braun1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Alsharifi1">&#x0005b;20&#x0005d;</xref>.</p></sec><sec id="s2"><title>Results</title><p>To investigate the mechanism of lymphocyte activation following LDV infection we first analyzed the kinetics of CD69 upregulation on splenic lymphocytes at several time points following infection. CD69 expression was analyzed by flow cytometry as previously described <xref ref-type="bibr" rid="pone.0006105-Robertson1">&#x0005b;16&#x0005d;</xref> and became detectable at 14 hours post-infection, peaked at 16 to 24 hours, and returned almost to background levels by 72 hours (<xref ref-type="fig" rid="pone-0006105-g001">Figure 1A</xref>). The induction of CD69 occurred on CD4&#x0002b; and CD8&#x0002b; T cells, as well as B cells (<xref ref-type="fig" rid="pone-0006105-g001">Figure 1B</xref>). In addition to the spleen, CD69 upregulation was also observed, albeit to a lesser extent, on lymphocytes from the blood, lymph nodes, and bone marrow (<xref ref-type="fig" rid="pone-0006105-g001">Figure 1C</xref>). In contrast, no significant upregulation was observed on lymphocytes from the thymus, which are primarily immature T cells. In contrast to CD69, the IL-2 receptor alpha chain (CD25), which is upregulated later in the activation cascade and is typically dependent on TCR ligation <xref ref-type="bibr" rid="pone.0006105-Lowenthal1">&#x0005b;21&#x0005d;</xref>, did not increase in expression during the first day of LDV infection (data not shown). This result is consistent with partial rather than full activation of the lymphocytes.</p><fig id="pone-0006105-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006105.g001</object-id><label>Figure 1</label><caption><title>LDV-induced upregulation of CD69.</title><p>Cells were stained and analyzed by flow cytometry as described (22). (A) Kinetics showing the percentage of splenic lymphocytes with CD69 upregulation. Significant upregulation (P&#x0003c;.05) was observed between 12 and 48hpi (n&#x0200a;&#x0003d;&#x0200a;2&#x02212;4 mice per group per time point). (B) Upregulation of CD69 on major splenic lymphocyte subsets at 16hpi with LDV was analyzed by co-staining with antibodies for CD69 and either CD4, CD8 or CD19 as indicated. The difference in percentage of CD69<sup>hi</sup> cells between na&#x000ef;ve and infected mice was statistically significant for all subsets by t test, P&#x0200a;&#x0003d;&#x0200a;0.0225 for CD4<sup>&#x0002b;</sup> T cells, 0.003 for CD8<sup>&#x0002b;</sup> T cells, and 0.0018 for CD19<sup>&#x0002b;</sup> B cells (n&#x0200a;&#x0003d;&#x0200a;2 mice per na&#x000ef;ve group and 3 mice per infected group.) (C) Tissue distribution of CD69 upregulation. Lymphocytes from spleen, blood, lymph nodes, bone marrow, and thymus were examined at 16hpi with LDV. All tissues except the thymus showed a significantly higher percentage of CD69<sup>hi</sup> lymphocytes when infected with LDV infected (P&#x0003c;0.01 for all groups indicated by &#x0002a;).</p></caption><graphic xlink:href="pone.0006105.g001"/></fig><p>The rapid systemic appearance of CD69 expression suggested that a soluble factor such as IFN&#x003b1;, a known early responder to viral infections <xref ref-type="bibr" rid="pone.0006105-Isaacs1">&#x0005b;22&#x0005d;</xref> and strong trigger of CD69 expression <xref ref-type="bibr" rid="pone.0006105-Shiow1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Braun1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Alsharifi1">&#x0005b;20&#x0005d;</xref>, was inducing the response. To determine whether the LDV-induced IFN&#x003b1; response <xref ref-type="bibr" rid="pone.0006105-Robertson1">&#x0005b;16&#x0005d;</xref> could be responsible for CD69 induction, we first utilized the fact that IFN&#x003b1; induces CD69 expression on B cells <italic>in vitro</italic><xref ref-type="bibr" rid="pone.0006105-Braun1">&#x0005b;19&#x0005d;</xref>. Splenic B cells were isolated from na&#x000ef;ve mice using CD19&#x0002b; magnetic beads (Miltenyi Biotec) and cultured with 10&#x00025; plasma taken from mice infected 16 hours earlier with LDV. B cells cultured for 4 hours with plasma from infected, but not uninfected mice, significantly upregulated CD69 expression (<xref ref-type="fig" rid="pone-0006105-g002">Figure 2</xref>). Furthermore, upregulation of CD69 expression was prevented by addition of a neutralizing antibody specific for IFN&#x003b1; (PBL Interferon Source) in a concentration-dependent manner. These findings suggested that the IFN&#x003b1; response to LDV infection might be responsible for the partial activation of lymphocytes <italic>in vivo</italic> as well.</p><fig id="pone-0006105-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006105.g002</object-id><label>Figure 2</label><caption><title>CD69 upregulation in B cells blocked by anti-IFN&#x003b1; antibody.</title><p>The addition of 10&#x00025; serum from LDV-infected mice harvested at 16hpi induced upregulation of CD69 in a significant percentage of splenic B cells (2&#x000d7;10<sup>5</sup> B cells/well) cultured <italic>in vitro</italic> for 4 hours following their isolation with CD19 magnetic beads (Miltenyi Biotec). Addition of 2 or 20 &#x000b5;l of anti-IFN&#x003b1; antibody (PBL Interferon Source) to 198 or 180 &#x000b5;l cultures respectively, significantly reduced the percentage of cells with CD69 upregulation (P&#x02264;0.0001 by t test).</p></caption><graphic xlink:href="pone.0006105.g002"/></fig><p>Although any cell can produce IFN&#x003b1; in response to infection, the acute systemic response to viruses has been attributed to production by plasmacytoid dendritic cells (pDC's, also known as interferon-producing cells or IPC) <xref ref-type="bibr" rid="pone.0006105-LeBon1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Cella1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-AsselinPaturel1">&#x0005b;25&#x0005d;</xref>, which comprise only a minor subpopulation of cells but can produce 1000 times as much IFN&#x003b1; as other cells <xref ref-type="bibr" rid="pone.0006105-Cella1">&#x0005b;24&#x0005d;</xref>. Conventional DC's can also produce high amounts of IFN&#x003b1; if they are directly infected, but pDC's are uniquely able to secrete high levels of IFN&#x003b1; in response to endocytosed antigen. The role of pDC's in production of IFN&#x003b1; during LDV infection was investigated by depleting mice of pDC's the day before LDV infection using a pDC-specific depleting antibody <xref ref-type="bibr" rid="pone.0006105-Krug1">&#x0005b;26&#x0005d;</xref>. The plasma IFN&#x003b1; response at 16 hours post-infection with LDV, as measured by ELISA, was abolished by pDC depletion (<xref ref-type="fig" rid="pone-0006105-g003">Figure 3A</xref>). Thus the systemic IFN&#x003b1; response was predominantly due to production by pDC's. In addition to loss of the IFN&#x003b1; response in pDC-depleted mice, we also observed the failure of splenic lymphocytes to upregulate CD69. A histogram showing CD69 expression on splenocytes from a representative mouse is shown in <xref ref-type="fig" rid="pone-0006105-g003">Figure 3B</xref>. Combined with the dependence on IFN&#x003b1;for upregulation of CD69 on B cells <italic>in vitro</italic>, the data indicate that <italic>in vivo</italic> upregulation of CD69 on lymphocytes is likely due to the systemic IFN&#x003b1; response to LDV infection. Interestingly, the loss of the IFN&#x003b1; response in pDC-depleted mice produced no statistically significant difference in LDV plasma levels as measured by real time PCR (15) (<xref ref-type="fig" rid="pone-0006105-g003">Figure 3C</xref>). Since IFN&#x003b1; can act in both autocrine and paracrine manners to limit virus replication and spread <xref ref-type="bibr" rid="pone.0006105-Deonarain1">&#x0005b;27&#x0005d;</xref>, it appears that LDV is quite resistant to the antiviral effects of IFN&#x003b1;, even when present at very high systemic levels.</p><fig id="pone-0006105-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006105.g003</object-id><label>Figure 3</label><caption><title><italic>In vivo</italic> depletion of plasmacytoid dendritic cells abolishes IFN&#x003b1; production.</title><p>Na&#x000ef;ve (A.BY x B10)F1 mice were depleted of pDC's by injection of 0.5 mg mPDCA-1 antibody (Miltenyi Biotec) 24 h prior to infection with LDV, and blood samples were collected at 16hpi. (A) Interferon alpha levels in na&#x000ef;ve mice (left), LDV-infected normal mice (middle), and LDV-infected, pDC-depleted mice (right) were measured by ELISA (PBL Interferon Source). The difference between the two LDV-infected groups was statistically significant by t test (P&#x0003c;0.0001, n&#x0200a;&#x0003d;&#x0200a;5). (B) Flow cytometric analysis of peripheral blood lymphocytes showed significant reductions in LDV-induced expression of CD69 in pDC depleted mice (average mean fluorescence intensity of 114.3&#x0002b;/&#x02212;14.25 vs. 42.96&#x0002b;/&#x02212;11.85, n&#x0200a;&#x0003d;&#x0200a;5, p&#x0200a;&#x0003d;&#x0200a;0.0049 by t test). A representative histogram of CD69 expression on cells from LDV-infected mice that were pDC-depleted pDC<sup>&#x02212;</sup>) or mock-treated (pDC<sup>&#x0002b;</sup>) is shown. The histograms of cells from na&#x000ef;ve animals overlapped with the curves from pDC depleted mice (data not shown). (C) pDC depletion did not significantly alter LDV levels in plasma as indicated by results from semiquantitative real-time RT-PCR as previously described <xref ref-type="bibr" rid="pone.0006105-Robertson1">&#x0005b;16&#x0005d;</xref>. Relative LDV levels are indicated by real time PCR critical threshold (Ct) values, which were not significantly different between LDV-infected normal mice (pDC<sup>&#x0002b;</sup>) Ct&#x0200a;&#x0003d;&#x0200a;22.05&#x0002b;/&#x02212;0.33, and LDV-infected, pDC-depleted mice (pDC<sup>&#x02212;</sup>) Ct&#x0200a;&#x0003d;&#x0200a;21.72&#x0002b;/&#x02212;0.43 (n&#x0200a;&#x0003d;&#x0200a;5).</p></caption><graphic xlink:href="pone.0006105.g003"/></fig><p>Given that LDV is a single-stranded RNA virus, we investigated whether the pDC-dependent IFN&#x003b1; response was mediated by toll like receptor 7 (TLR7), which is highly expressed by pDC's, binds to single stranded viral RNA, and is capable of initiating IFN&#x003b1; responses in pDC's without their direct infection <xref ref-type="bibr" rid="pone.0006105-Kato1">&#x0005b;28&#x0005d;</xref>. Mice containing a genetically inactivated TLR7 gene <xref ref-type="bibr" rid="pone.0006105-Butchi1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006105-Hemmi1">&#x0005b;30&#x0005d;</xref> failed to mount IFN&#x003b1; responses or to upregulate CD69 expression in response to LDV infection, whereas genetically matched TLR7 wild type mice showed strong IFN&#x003b1; responses and CD69 upregulation (<xref ref-type="fig" rid="pone-0006105-g004">Figure 4A, B</xref>). Consistent with the results from pDC depletions, LDV plasma titers were again not significantly different in the absence of TLR7 expression and IFN&#x003b1; production (<xref ref-type="fig" rid="pone-0006105-g004">Figure 4C</xref>). These results are similar to data from type I interferon receptor-deficient mice infected with LDV, although that study noted slight (two fold) increases in virus titers in the absence of type I interferon signaling <xref ref-type="bibr" rid="pone.0006105-LeThiPhuong1">&#x0005b;31&#x0005d;</xref>.</p><fig id="pone-0006105-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006105.g004</object-id><label>Figure 4</label><caption><title>LDV-induced CD69 upregulation is TLR7-dependent.</title><p>TLR7 wild type and knockout mice on the 129SvEv genetic background were infected with LDV and blood was analyzed at 16hpi. (A) IFN&#x003b1; levels in plasma were significantly reduced in TLR7<sup>&#x02212;/&#x02212;</sup> mice as measured by ELISA (PBL Interferon Source). Values in TLR7<sup>&#x0002b;/&#x0002b;</sup> mice averaged 795.5 pg/ml while only trace amounts of IFN&#x003b1; were detected in TLR7<sup>&#x02212;/&#x02212;</sup> mice ( TLR7<sup>&#x0002b;/&#x0002b;</sup> vs. TLR7<sup>&#x02212;/&#x02212;</sup> p&#x0200a;&#x0003d;&#x0200a;0.0041 by T test). (B) The low levels of IFN&#x003b1; in TLR7<sup>&#x02212;/&#x02212;</sup> mice correlated with reduced percentages of lymphocytes expressing CD69 (TLR7<sup>&#x0002b;/&#x0002b;</sup> 57.30&#x00025;&#x0002b;/&#x02212;4.15&#x00025; CD69<sup>&#x0002b;</sup> vs. TLR7<sup>&#x02212;/&#x02212;</sup> 4.37&#x00025;&#x0002b;/&#x02212;0.28&#x00025; CD69<sup>&#x0002b;</sup>, n&#x0200a;&#x0003d;&#x0200a;3, p&#x0200a;&#x0003d;&#x0200a;0.0002 by t test). (C) LDV-specific semiquantitative real-time RT-PCR as previously described <xref ref-type="bibr" rid="pone.0006105-Robertson1">&#x0005b;16&#x0005d;</xref> revealed no significant difference in virus levels between TLR7 knockout and TLR7 wild type mice as measured by critical threshold values (TLR7<sup>&#x0002b;/&#x0002b;</sup> Ct&#x0200a;&#x0003d;&#x0200a;25.93&#x0002b;/&#x02212;0.59 vs. TLR7<sup>&#x02212;/&#x02212;</sup> 26.90&#x0002b;/&#x02212;0.38, n&#x0200a;&#x0003d;&#x0200a;3 mice/group).</p></caption><graphic xlink:href="pone.0006105.g004"/></fig></sec><sec id="s3"><title>Discussion</title><p>Together, our data indicate that pDC's activated in a TLR7-dependent manner are primarily responsible for the rapid systemic IFN&#x003b1; response following infection of mice with LDV. Furthermore, the interferon response was most likely responsible for the transient expression of the CD69 very early activation marker on lymphocytes during acute LDV infection. IFN&#x003b1;&#x02013;dependent, partial activation of lymphocytes has also been reported during acute infection with Semliki forest virus <xref ref-type="bibr" rid="pone.0006105-Alsharifi1">&#x0005b;20&#x0005d;</xref>, human adenovirus 2, West Nile virus, and A/WSN influenza virus <xref ref-type="bibr" rid="pone.0006105-Alsharifi2">&#x0005b;32&#x0005d;</xref> in mice. However, not all acute viral infections induce partial activation, as it does not occur in Friend retrovirus infections of mice <xref ref-type="bibr" rid="pone.0006105-Robertson1">&#x0005b;16&#x0005d;</xref>. Such broad activation is by definition non-specific, and leaves open the question of how it benefits the host. Alsharifi et al. have proposed that IFN&#x003b1;-induced partial activation may promote adaptive immune responses by lowering the threshold for full activation once antigen-specific recognition occurs <xref ref-type="bibr" rid="pone.0006105-Alsharifi3">&#x0005b;33&#x0005d;</xref>. If so, IFN&#x003b1; may be a very important regulatory link between the innate and adaptive immune responses. Based on the findings that CD69 acts downstream of IFN&#x003b1; to inhibit lymphocyte egress from lymphoid organs <xref ref-type="bibr" rid="pone.0006105-Shiow1">&#x0005b;17&#x0005d;</xref>, it is also likely that CD69 expression facilitates sustained contacts between lymphocytes and antigen presenting cells during inflammatory responses, thereby enhancing full activation of antigen-specific lymphocytes.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0006105-Drosten1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Gunther</surname><given-names>S</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name><name><surname>van der Werf</surname><given-names>S</given-names></name><name><surname>Brodt</surname><given-names>HR</given-names></name><etal/></person-group><year>2003</year><article-title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome.</article-title><source>N Engl J Med</source><volume>348</volume><fpage>1967</fpage><lpage>1976</lpage><pub-id pub-id-type="pmid">12690091</pub-id></mixed-citation></ref><ref id="pone.0006105-Ksiazek1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ksiazek</surname><given-names>TG</given-names></name><name><surname>Erdman</surname><given-names>D</given-names></name><name><surname>Goldsmith</surname><given-names>CS</given-names></name><name><surname>Zaki</surname><given-names>SR</given-names></name><name><surname>Peret</surname><given-names>T</given-names></name><etal/></person-group><year>2003</year><article-title>A novel coronavirus associated with severe acute respiratory syndrome.</article-title><source>N Engl J Med</source><volume>348</volume><fpage>1953</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">12690092</pub-id></mixed-citation></ref><ref id="pone.0006105-Peiris1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Lai</surname><given-names>ST</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Yam</surname><given-names>LY</given-names></name><etal/></person-group><year>2003</year><article-title>Coronavirus as a possible cause of severe acute respiratory syndrome.</article-title><source>Lancet</source><volume>361</volume><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">12711465</pub-id></mixed-citation></ref><ref id="pone.0006105-Plagemann1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plagemann</surname><given-names>PG</given-names></name><name><surname>Moennig</surname><given-names>V</given-names></name></person-group><year>1992</year><article-title>Lactate dehydrogenase-elevating virus, equine arteritis virus, and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses.</article-title><source>Adv Virus Res</source><volume>41</volume><fpage>99</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">1315480</pub-id></mixed-citation></ref><ref id="pone.0006105-Plagemann2"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plagemann</surname><given-names>PG</given-names></name><name><surname>Rowland</surname><given-names>RR</given-names></name><name><surname>Even</surname><given-names>C</given-names></name><name><surname>Faaberg</surname><given-names>KS</given-names></name></person-group><year>1995</year><article-title>Lactate dehydrogenase-elevating virus: an ideal persistent virus?</article-title><source>Springer Semin Immunopathol</source><volume>17</volume><fpage>167</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">8571167</pub-id></mixed-citation></ref><ref id="pone.0006105-Ritzi1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritzi</surname><given-names>DM</given-names></name><name><surname>Holth</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>MS</given-names></name><name><surname>Swart</surname><given-names>WJ</given-names></name><name><surname>Cafruny</surname><given-names>WA</given-names></name><etal/></person-group><year>1982</year><article-title>Replication of lactate dehydrogenase-elevating virus in macrophages. 1. Evidence for cytocidal replication.</article-title><source>J Gen Virol</source><volume>59</volume><fpage>245</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">7077301</pub-id></mixed-citation></ref><ref id="pone.0006105-Riley1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>V</given-names></name><name><surname>Lilly</surname><given-names>F</given-names></name><name><surname>Huerto</surname><given-names>E</given-names></name><name><surname>Bardell</surname><given-names>D</given-names></name></person-group><year>1960</year><article-title>Transmissible Agent Associated with 26 Types of Experimental Mouse Neoplasms.</article-title><source>Science</source><volume>132</volume><fpage>545</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">17798830</pub-id></mixed-citation></ref><ref id="pone.0006105-Onyekaba1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onyekaba</surname><given-names>CO</given-names></name><name><surname>Harty</surname><given-names>JT</given-names></name><name><surname>Even</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>BG</given-names></name><name><surname>Plagemann</surname><given-names>PG</given-names></name></person-group><year>1989</year><article-title>Persistent infection of mice by lactate dehydrogenase-elevating virus: effects of immunosuppression on virus replication and antiviral immune responses.</article-title><source>Virus Res</source><volume>14</volume><fpage>297</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">2623944</pub-id></mixed-citation></ref><ref id="pone.0006105-Stueckemann1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stueckemann</surname><given-names>JA</given-names></name><name><surname>Holth</surname><given-names>M</given-names></name><name><surname>Swart</surname><given-names>WJ</given-names></name><name><surname>Kowalchyk</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>MS</given-names></name><etal/></person-group><year>1982</year><article-title>Replication of lactate dehydrogenase-elevating virus in macrophages. 2. Mechanism of persistent infection in mice and cell culture.</article-title><source>J Gen Virol</source><volume>59</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">6176676</pub-id></mixed-citation></ref><ref id="pone.0006105-vandenBroek1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Broek</surname><given-names>MF</given-names></name><name><surname>Sporri</surname><given-names>R</given-names></name><name><surname>Even</surname><given-names>C</given-names></name><name><surname>Plagemann</surname><given-names>PG</given-names></name><name><surname>Hanseler</surname><given-names>E</given-names></name><etal/></person-group><year>1997</year><article-title>Lactate dehydrogenase-elevating virus (LDV): lifelong coexistence of virus and LDV-specific immunity.</article-title><source>J Immunol</source><volume>159</volume><fpage>1585</fpage><lpage>1588</lpage><pub-id pub-id-type="pmid">9257815</pub-id></mixed-citation></ref><ref id="pone.0006105-Anderson1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>GW</given-names></name><name><surname>Even</surname><given-names>C</given-names></name><name><surname>Rowland</surname><given-names>RR</given-names></name><name><surname>Palmer</surname><given-names>GA</given-names></name><name><surname>Harty</surname><given-names>JT</given-names></name><etal/></person-group><year>1995</year><article-title>C58 and AKR mice of all ages develop motor neuron disease after lactate dehydrogenase-elevating virus infection but only if antiviral immune responses are blocked by chemical or genetic means or as a result of old age.</article-title><source>J Neurovirol</source><volume>1</volume><fpage>244</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">9222362</pub-id></mixed-citation></ref><ref id="pone.0006105-Contag1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contag</surname><given-names>CH</given-names></name><name><surname>Plagemann</surname><given-names>PG</given-names></name></person-group><year>1988</year><article-title>Susceptibility of C58 mice to paralytic disease induced by lactate dehydrogenase-elevating virus correlates with increased expression of endogenous retrovirus in motor neurons.</article-title><source>Microb Pathog</source><volume>5</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">3237056</pub-id></mixed-citation></ref><ref id="pone.0006105-Marques1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>R</given-names></name><name><surname>Antunes</surname><given-names>I</given-names></name><name><surname>Eksmond</surname><given-names>U</given-names></name><name><surname>Stoye</surname><given-names>J</given-names></name><name><surname>Hasenkrug</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>B lymphocyte activation by coinfection prevents immune control of friend virus infection.</article-title><source>J Immunol</source><volume>181</volume><fpage>3432</fpage><lpage>3440</lpage><pub-id pub-id-type="pmid">18714015</pub-id></mixed-citation></ref><ref id="pone.0006105-Notkins1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notkins</surname><given-names>AL</given-names></name><name><surname>Greenfield</surname><given-names>RE</given-names></name></person-group><year>1962</year><article-title>Infection of tumor-bearing mice with the lactic dehydrogenase agent.</article-title><source>Proc Soc Exp Biol Med</source><volume>109</volume><fpage>988</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">14480486</pub-id></mixed-citation></ref><ref id="pone.0006105-Howard1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>RJ</given-names></name><name><surname>Notkins</surname><given-names>AL</given-names></name><name><surname>Mergenhagen</surname><given-names>SE</given-names></name></person-group><year>1969</year><article-title>Inhibition of cellular immune reactions in mice infected with lactic dehydrogenase virus.</article-title><source>Nature</source><volume>221</volume><fpage>873</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">4885265</pub-id></mixed-citation></ref><ref id="pone.0006105-Robertson1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>SJ</given-names></name><name><surname>Ammann</surname><given-names>CG</given-names></name><name><surname>Messer</surname><given-names>RJ</given-names></name><name><surname>Carmody</surname><given-names>AB</given-names></name><name><surname>Myers</surname><given-names>L</given-names></name><etal/></person-group><year>2008</year><article-title>Suppression of acute anti-friend virus CD8&#x0002b; T-cell responses by coinfection with lactate dehydrogenase-elevating virus.</article-title><source>J Virol</source><volume>82</volume><fpage>408</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">17959678</pub-id></mixed-citation></ref><ref id="pone.0006105-Shiow1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiow</surname><given-names>LR</given-names></name><name><surname>Rosen</surname><given-names>DB</given-names></name><name><surname>Brdickova</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>J</given-names></name><etal/></person-group><year>2006</year><article-title>CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs.</article-title><source>Nature</source><volume>440</volume><fpage>540</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">16525420</pub-id></mixed-citation></ref><ref id="pone.0006105-LopezCabrera1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Cabrera</surname><given-names>M</given-names></name><name><surname>Santis</surname><given-names>AG</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>E</given-names></name><name><surname>Blacher</surname><given-names>R</given-names></name><name><surname>Esch</surname><given-names>F</given-names></name><etal/></person-group><year>1993</year><article-title>Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors.</article-title><source>J Exp Med</source><volume>178</volume><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">8340758</pub-id></mixed-citation></ref><ref id="pone.0006105-Braun1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>D</given-names></name><name><surname>Caramalho</surname><given-names>I</given-names></name><name><surname>Demengeot</surname><given-names>J</given-names></name></person-group><year>2002</year><article-title>IFN-alpha/beta enhances BCR-dependent B cell responses.</article-title><source>Int Immunol</source><volume>14</volume><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">11934877</pub-id></mixed-citation></ref><ref id="pone.0006105-Alsharifi1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsharifi</surname><given-names>M</given-names></name><name><surname>Lobigs</surname><given-names>M</given-names></name><name><surname>Regner</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Koskinen</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection.</article-title><source>J Immunol</source><volume>175</volume><fpage>4635</fpage><lpage>4640</lpage><pub-id pub-id-type="pmid">16177109</pub-id></mixed-citation></ref><ref id="pone.0006105-Lowenthal1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowenthal</surname><given-names>JW</given-names></name><name><surname>Bohnlein</surname><given-names>E</given-names></name><name><surname>Ballard</surname><given-names>DW</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><year>1988</year><article-title>Regulation of interleukin 2 receptor alpha subunit (Tac or CD25 antigen) gene expression: binding of inducible nuclear proteins to discrete promoter sequences correlates with transcriptional activation.</article-title><source>Proc Natl Acad Sci U S A</source><volume>85</volume><fpage>4468</fpage><lpage>4472</lpage><pub-id pub-id-type="pmid">3132714</pub-id></mixed-citation></ref><ref id="pone.0006105-Isaacs1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaacs</surname><given-names>A</given-names></name><name><surname>Lindenmann</surname><given-names>J</given-names></name></person-group><year>1957</year><article-title>Virus interference. I. The interferon.</article-title><source>Proc R Soc Lond B Biol Sci</source><volume>147</volume><fpage>258</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">13465720</pub-id></mixed-citation></ref><ref id="pone.0006105-LeBon1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bon</surname><given-names>A</given-names></name><name><surname>Tough</surname><given-names>DF</given-names></name></person-group><year>2002</year><article-title>Links between innate and adaptive immunity via type I interferon.</article-title><source>Curr Opin Immunol</source><volume>14</volume><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">12088676</pub-id></mixed-citation></ref><ref id="pone.0006105-Cella1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Jarrossay</surname><given-names>D</given-names></name><name><surname>Facchetti</surname><given-names>F</given-names></name><name><surname>Alebardi</surname><given-names>O</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><etal/></person-group><year>1999</year><article-title>Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon.</article-title><source>Nat Med</source><volume>5</volume><fpage>919</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">10426316</pub-id></mixed-citation></ref><ref id="pone.0006105-AsselinPaturel1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asselin-Paturel</surname><given-names>C</given-names></name><name><surname>Boonstra</surname><given-names>A</given-names></name><name><surname>Dalod</surname><given-names>M</given-names></name><name><surname>Durand</surname><given-names>I</given-names></name><name><surname>Yessaad</surname><given-names>N</given-names></name><etal/></person-group><year>2001</year><article-title>Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology.</article-title><source>Nat Immunol</source><volume>2</volume><fpage>1144</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">11713464</pub-id></mixed-citation></ref><ref id="pone.0006105-Krug1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krug</surname><given-names>A</given-names></name><name><surname>French</surname><given-names>AR</given-names></name><name><surname>Barchet</surname><given-names>W</given-names></name><name><surname>Fischer</surname><given-names>JA</given-names></name><name><surname>Dzionek</surname><given-names>A</given-names></name><etal/></person-group><year>2004</year><article-title>TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function.</article-title><source>Immunity</source><volume>21</volume><fpage>107</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">15345224</pub-id></mixed-citation></ref><ref id="pone.0006105-Deonarain1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deonarain</surname><given-names>R</given-names></name><name><surname>Alcami</surname><given-names>A</given-names></name><name><surname>Alexiou</surname><given-names>M</given-names></name><name><surname>Dallman</surname><given-names>MJ</given-names></name><name><surname>Gewert</surname><given-names>DR</given-names></name><etal/></person-group><year>2000</year><article-title>Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon.</article-title><source>J Virol</source><volume>74</volume><fpage>3404</fpage><lpage>3409</lpage><pub-id pub-id-type="pmid">10708458</pub-id></mixed-citation></ref><ref id="pone.0006105-Kato1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Yoneyama</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><etal/></person-group><year>2005</year><article-title>Cell type-specific involvement of RIG-I in antiviral response.</article-title><source>Immunity</source><volume>23</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">16039576</pub-id></mixed-citation></ref><ref id="pone.0006105-Butchi1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butchi</surname><given-names>NB</given-names></name><name><surname>Pourciau</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>TW</given-names></name><name><surname>Peterson</surname><given-names>KE</given-names></name></person-group><year>2008</year><article-title>Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists.</article-title><source>J Immunol</source><volume>180</volume><fpage>7604</fpage><lpage>7612</lpage><pub-id pub-id-type="pmid">18490763</pub-id></mixed-citation></ref><ref id="pone.0006105-Hemmi1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Kaisho</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Sanjo</surname><given-names>H</given-names></name><etal/></person-group><year>2002</year><article-title>Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.</article-title><source>Nat Immunol</source><volume>3</volume><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">11812998</pub-id></mixed-citation></ref><ref id="pone.0006105-LeThiPhuong1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le-Thi-Phuong</surname><given-names>T</given-names></name><name><surname>Thirion</surname><given-names>G</given-names></name><name><surname>Coutelier</surname><given-names>JP</given-names></name></person-group><year>2007</year><article-title>Distinct gamma interferon-production pathways in mice infected with lactate dehydrogenase-elevating virus.</article-title><source>J Gen Virol</source><volume>88</volume><fpage>3063</fpage><lpage>3066</lpage><pub-id pub-id-type="pmid">17947531</pub-id></mixed-citation></ref><ref id="pone.0006105-Alsharifi2"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsharifi</surname><given-names>M</given-names></name><name><surname>Regner</surname><given-names>M</given-names></name><name><surname>Blanden</surname><given-names>R</given-names></name><name><surname>Lobigs</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><etal/></person-group><year>2006</year><article-title>Exhaustion of type I interferon response following an acute viral infection.</article-title><source>J Immunol</source><volume>177</volume><fpage>3235</fpage><lpage>3241</lpage><pub-id pub-id-type="pmid">16920963</pub-id></mixed-citation></ref><ref id="pone.0006105-Alsharifi3"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsharifi</surname><given-names>M</given-names></name><name><surname>Mullbacher</surname><given-names>A</given-names></name><name><surname>Regner</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Interferon type I responses in primary and secondary infections.</article-title><source>Immunol Cell Biol</source></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This research was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>